Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003211 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 4
- Study locations
NCT00003211 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 94 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00003211, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation therapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with topotecan, cyclophosphamide, cisplatin, and vincristine plus radiation therapy and peripheral stem cell transplantation in treating children with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG amifostine trihydrate
- DRUG vincristine sulfate
Study Locations (4)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Texas Children's Cancer Center - Houston
New South Wales
- Children's Hospital at Westmead - Westmead
Victoria
- Royal Children's Hospital - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 1996-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003211
The ClinicalTrials.gov registry entry for NCT00003211 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (48% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00003211 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, Texas, New South Wales.
Frequently Asked Questions
What is clinical trial NCT00003211 about?
NCT00003211 is a clinical study titled "Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation therapy and kill more ...
What is the current status of trial NCT00003211?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 1996-10. Estimated completion is 2007-06.
What conditions does trial NCT00003211 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003211?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), amifostine trihydrate (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00003211?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003211 being conducted?
This trial has 4 study locations across Tennessee, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.